We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares.
Plus, NBC News spoke to trans service members about their thoughts on President Trump's executive order banning trans people from enlisting and serving in the military.
If successful, the drug developed by Vertex Pharmaceuticals would offer a ... at the Center for Pain Relief at the University of Washington Medical Center-Roosevelt. “It’s a fantasy to think ...
Friday's edition of Forbes Daily covers the investigation of the deadly plane crash, OpenAI's whopping valuation, sluggish ...
Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...
Here’s what else you need to know to Get Up to Speed and On with Your Day. 1. Plane collision. Officials are now operating a recovery effort in the Potomac River, the site of th ...
Vertex has built an empire in cystic fibrosis (CF) treatment, recently crowning its dominance with Alyftrek's approval last month. This latest CF drug adds even more firepower to a franchise ...